Zydus Cadila

Our facilities are approved by:MHRA-UK(For Oral Solids),MCC - South Africa, ANVISA - Brazil,BFAD-philippines,NMA - Romania N,NDA - Uganda,

API, Formulations Development: Tablets,Hard & Soft Gelatine Capsules,Vials & Ampoules,Oncology Products, Lyophilized vials, Transdermal Patches,Metered Dose Inhalers & Dry Powder Inhalers.

Activity:

- Clinical Trials
- Contract Manufacturing
- Contract Research
- Informatics
- Licensing & Business Development
- Manufacturing
- Regulatory Affairs & Legal Services
- Research & Development
- Sales & Distribution

Product / Technology type(s) covered:

- API / chemicals
- Cosmoceuticals
- Devices
- Drug delivery
- Generics
- FP (finished products)
- NCE (new chemical entities)
- OTC (over the counter drugs)
- Pharmaceuticals / Therapeutics
- Nutritionals / Vitamins
- Prescription drugs (Rx)
- Preventive
- Proteins
- Technology

Therapeutic targets:

- Aging
- AIDS
- Allergy
- Arthritis / Rheumato
- Asthma
- Cancer
- Cardiovascular
- Central nervous system
- Cough / Cold
- Dermatology
- Diabetes
- Epidemiology
- Gastrointestinal
- Hematology
- Infectious Diseases
- Oncology
- Ophthalmology
- Pain
- Respiratory Medicine
- Stroke
- Surgery
- Tonics
- Urology
- Women's Health

Markets Covered

a. HeadQuarter: India

b. Continent(s) active: North America , Europe , Far East , Central/South America , Africa , Asia , Australia/New-Zealand

c. Countries active: US, UK, Germany, France, Switzerland, Spain, Italy, Japan, Southafrica, Uganda, Russia, Ukraine, Srilanka, India, Brazil,Vietnam,Middle east

Corporate data:

Number of Employees: 6000

Turnover:

Amount:	Year:	Currency:
283 mill	2002	US Dollar

Year founded: 1952

Partners / Alliances: Zydus Altana Healthcare Private Limited, Onconova Therapeutics, Zydus France SAS earlier known as Alpharma France, Recon Healthcare Ltd, German Remedies, Altana Pharma AG , Byk Gulden of Germany, Banyan Chemicals